Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.

Journal article

To evaluate the efficacy and safety of intravenous ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, active rheumatoid arthritis (RA) patients despite methotrexate treatment.

Authors: Taylor, P; Quattrocchi, E; Mallett, S; Kurrasch, R; Petersen, J

• Journal: Ann Rheum Dis
• Volume: 70
• Issue: 12
• Pages: 2119-2125
• Place of publication: England
• Publication date: 2011-12-01
• DOI: 10.1136/ard.2011.151522
• EISSN: 1468-2060
• ISSN: 0003-4967
• Language: English
• Keywords: Female; Aged; Antirheumatic Agents; Quality of Life; Double-Blind Method; Adult; Methotrexate; Drug Eruptions; Infusions, Intravenous; Male; Drug Therapy, Combination; Treatment Outcome; Middle Aged; Antigens, CD20; Biological Markers; C-Reactive Protein; Antibodies, Monoclonal; Severity of Illness Index; Arthritis, Rheumatoid; Humans